Lee Deokho, Tomita Yohei, Negishi Kazuno, Kurihara Toshihide
Laboratory of Photobiology, Keio University School of Medicine, Tokyo, Japan.
Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.
Histol Histopathol. 2023 Apr;38(4):391-401. doi: 10.14670/HH-18-542. Epub 2022 Oct 28.
Ocular ischemia is one of the leading causes of blindness. It is related to various ocular diseases and disorders, including age-related macular degeneration, diabetic retinopathy, glaucoma, and corneal injury. Ocular ischemia occurs due to an abnormal supply of oxygen and nutrients to the eye, resulting in ocular metabolic dysfunction. These changes can be linked with pathologic conditions in the eye, such as inflammation, neovascularization, and cell death, ultimately leading to vision loss. The current treatment care for ocular ischemia is limited. Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor protein functioning in regulating lipid metabolism, fatty acid oxidation, and glucose homeostasis. Recently, PPARα activation has been suggested as a useful therapeutic target in treating ocular ischemia. However, its applications have not been well summarized. In this review, we cover an overview of the therapeutic roles of PPARα activation in various ocular ischemic conditions with recent experimental evidence and further provide clinical implications of its therapeutic applications. Our review will enable more approaches to comprehensively understand the therapeutic roles of PPARα activation for preventing ocular ischemic diseases.
眼部缺血是导致失明的主要原因之一。它与多种眼部疾病和病症相关，包括年龄相关性黄斑变性、糖尿病视网膜病变、青光眼和角膜损伤。眼部缺血是由于眼睛的氧气和营养物质供应异常而发生的，导致眼部代谢功能障碍。这些变化可能与眼部的病理状况有关，如炎症、新生血管形成和细胞死亡，最终导致视力丧失。目前针对眼部缺血的治疗方法有限。过氧化物酶体增殖物激活受体α（PPARα）是一种核受体蛋白，在调节脂质代谢、脂肪酸氧化和葡萄糖稳态中发挥作用。最近，PPARα激活已被认为是治疗眼部缺血的一个有用的治疗靶点。然而，其应用尚未得到很好的总结。在这篇综述中，我们用最近的实验证据概述了PPARα激活在各种眼部缺血状况中的治疗作用，并进一步提供其治疗应用的临床意义。我们的综述将使人们能够通过更多途径全面了解PPARα激活在预防眼部缺血性疾病中的治疗作用。
